# Health Care — Matterfact Podcast Newsletter

> The full healthcare complex: the GLP-1 obesity wave, the biotech pipeline and patent-cliff M&A, AI drug discovery, devices, and the drug-pricing and managed-care policy fights.

**71 issues** · Coverage: LLY, NVO, ISRG, DXCM, INSP, IRTC, PEP, MDLZ, GIS, HSY, RXRX, SDGR.

---

- [Medicare's $50 GLP-1 Bridge Goes Live July 1 - The Obesity-Drug Pipeline - Week of June 29, 2026](https://www.matterfact.com/newsletter/2026-06-29-obesity-drug-pipeline-medicare-glp1-bridge.md) — 2026-06-29: Issue #1 of The Obesity-Drug Pipeline: for the week of June 22-29, 2026, podcast operators and analysts map Medicare's $50 GLP-1 Bridge Program, Lilly's widening lead, and retatrutide resetting the efficacy ceiling.
- [Lilly's Mystery Patient And The Road To 70 Billion - Podcast Intelligence - Week of June 29, 2026](https://www.matterfact.com/newsletter/2026-06-29-lilly-mystery-patient-70-billion.md) — 2026-06-29: Operators and analysts on the podcast tape for the week of June 22-29, 2026 weigh Lilly's retatrutide compassionate-use story, a tirzepatide franchise printing 12.8 billion dollars a quarter, and a fragile Medicare obesity on-ramp.
- [The 340B Rebate Rewrite Is the Real Story This Week - Drug Pricing & IRA Round 2 - Week of June 22 – 29, 2026](https://www.matterfact.com/newsletter/2026-06-29-drug-pricing-340b-rebate-rewrite.md) — 2026-06-29: Drug pricing and IRA newsletter for the week of June 22 to 29, 2026. HRSA's revised 340B rebate model is being drafted to swallow Medicare-negotiated drugs and keep adding more each year, while MFN is already reshaping ex-US licensing deals and net drug revenue keeps growing double digits.
- [Thermo Fisher Pushes the Connected Lab Software Annuity - Life-Science Tools Recovery - Week of June 28, 2026](https://www.matterfact.com/newsletter/2026-06-28-thermo-fisher-connected-lab-software.md) — 2026-06-28: For the week of June 21-28, 2026, Thermo Fisher's David Hardy laid out a connected-lab, standards-led software and services strategy on the Smart Biotech Scientist podcast, a recurring-revenue play layered on the installed base.
- [AbbVie Buys Apogee for 10.9 Billion as a Biotech M&A Super-Cycle Accelerates - Pharma / Biotech / Life Sciences Podcast Recap - Week of June 28, 2026](https://www.matterfact.com/newsletter/2026-06-28-pharma-biotech-recap.md) — 2026-06-28: Pharma, biotech and life-sciences podcast recap for the week of June 21-28, 2026. AbbVie agreed to buy Apogee Therapeutics for $10.9 billion as a patent-cliff-driven M&A super-cycle collided with an FDA regulatory thaw, while Lilly's Mounjaro became the world's top-selling drug and the XBI hit a five-year high.
- [pTau-217 Blood Tests Go Direct to Consumer as Anti-Amyloid Stays Early Innings - The Neuro & Alzheimer's Pipeline - Week of June 28, 2026](https://www.matterfact.com/newsletter/2026-06-28-neuro-ptau-217-dtc.md) — 2026-06-28: Neuro and Alzheimer's pipeline newsletter for the week of June 22-28, 2026. A prescribing clinician says pTau-217 blood tests are now sold direct-to-consumer by quite a few labs, opening a validated-versus-unvalidated quality split underneath a real diagnostics TAM, while his candid anti-amyloid scorecard frames roughly 30% slowing as 'the beginning,' comparing the moment to where AZT stood for HIV.
- [Biotech Thaws as the FDA's Reversal Train Now Has a Pattern - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of June 28, 2026](https://www.matterfact.com/newsletter/2026-06-28-biotech-thaws-fda-reversal-pattern.md) — 2026-06-28: Biotech gene/cell, neuro and tools podcast pipeline for the week of June 21-28, 2026. A second rare-disease gene therapy joined the FDA's regulatory reversal, AbbVie's $10.9 billion Apogee takeout reopened the deal machine, and in-vivo editing drew fresh capital and a copycat fight.
- [MA 2027 Funding Halved and Medicare Launches a GLP-1 Bridge Program - Managed Care Under Pressure - Week of June 27, 2026](https://www.matterfact.com/newsletter/2026-06-27-ma-2027-funding-halved-medicare-glp1-bridge.md) — 2026-06-27: Managed-care podcast briefing for the week of June 20-27, 2026. An MA distribution operator quantified the 2027 funding squeeze (carriers got 'less than half' of last year's +5.06%, average MA MLR 'over 90%'), Medicare's GLP-1 Bridge Program goes live July 1 with the federal government absorbing the cost, and IQVIA reframed GLP-1s as only about one point of total drug-spend growth.
- [GLP-1 Bridge Program Goes Live as IRA Rebate Collapse Squeezes PBMs and Hospitals - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 27, 2026](https://www.matterfact.com/newsletter/2026-06-27-ira-rebate-collapse-glp1-bridge-program.md) — 2026-06-27: Healthcare policy newsletter for the week of June 27, 2026. The IRA is collapsing the rebate spread that feeds PBMs and 340B hospitals from the inside, Medicare's GLP-1 Bridge Program launches July 1 at ~$50/month, and Medicaid work requirements plus the ACA subsidy cliff set up a 2027-2028 coverage reckoning for managed care.
- [AbbVie Leads a Pharma Merger Wave Ahead of Medicare GLP-1 Coverage - The Healthcare Pulse - Week of June 26, 2026](https://www.matterfact.com/newsletter/2026-06-26-healthcare-pulse-merger-mania-glp-1-bridge.md) — 2026-06-26: Weekly healthcare podcast intelligence brief for the week of June 19-26, 2026. An M&A frenzy podcasters dubbed merger mania (headlined by AbbVie's ~$10.9B Apogee buy) ran alongside the run-up to Medicare's GLP-1 Bridge Program, which goes live July 1, while GLP-1 commentary turned to placebo-arm contamination, a retatrutide compassionate-use mystery, and whether the bridge actually reaches patients.
- [Medicare GLP-1 Coverage Goes Live July 1 and Biopharma M&A Accelerates - Healthcare Podcast Weekly Digest - Week of June 26, 2026](https://www.matterfact.com/newsletter/2026-06-26-healthcare-medicare-glp1-bridge-ma-supercycle.md) — 2026-06-26: Healthcare and biopharma newsletter for the week of June 20 to 26, 2026. The CMS Medicare GLP-1 Bridge Program goes live July 1 at a $50 monthly co-pay, the biopharma M&A supercycle accelerated with AbbVie's $10.9B Apogee deal and a flurry of Lilly transactions, and policy overhang from 340B, IRA and MFN pricing framed the bear case.
- [AbbVie Buys Apogee for 10.9 Billion Capping a 134 Billion M&A Year - The Biotech Patent Cliff & M&A - Week of June 26, 2026](https://www.matterfact.com/newsletter/2026-06-26-biotech-abbvie-apogee-patent-cliff.md) — 2026-06-26: Biotech patent-cliff M&A newsletter for the week of June 26, 2026. AbbVie's $10.9B all-cash Apogee takeout (accretive only from 2032) became the largest biopharma-proper deal of 2026 and capped a $134B, 33-deal, six-month spree, while MRK, PFE, BMY, JNJ, VRTX, GILD and AZN stayed near-silent on the tape.
- [AbbVie Pays 10.9 Billion for Apogee as Pharma M&A Hits a Deal a Week - The Biotech Patent Cliff & M&A - Week of June 26, 2026](https://www.matterfact.com/newsletter/2026-06-26-biotech-abbvie-apogee-deal-a-week.md) — 2026-06-26: Biotech patent-cliff M&A newsletter for the week of June 26, 2026. AbbVie's $10.9B all-cash Apogee buy (49% premium, no CVR) became 2026's largest biopharma-proper takeout as a J.P. Morgan banker described large-cap pharma closing almost a deal a week, with XBI at five-year highs and the busiest biotech IPO year since 2021 at the halfway mark.
- [Legacy Packaged Food Loses Share While Cocoa Cost Relief Favors Mondelez and Hershey - Food: Brands, Private Label & Grocery - Week of June 25, 2026](https://www.matterfact.com/newsletter/2026-06-25-food-legacy-dark-cocoa-relief.md) — 2026-06-25: Food, private label and grocery newsletter for the week of June 25, 2026. A trio of Evercore analysts wrote off legacy packaged food on share loss and unpassable cost inflation, named cocoa-relief beneficiaries Mondelez and Hershey as the one long, and flagged private label going mainstream and retail media heading for a cull.
- [Physics-Based Screening Gains at BIO 2026 and AlphaFold Architect John Jumper Joins Anthropic - AI Drug Discovery Weekly - Week of June 25, 2026](https://www.matterfact.com/newsletter/2026-06-25-ai-drug-discovery-physics-beats-language.md) — 2026-06-25: AI drug discovery newsletter for the week of June 19 to 25, 2026. BIO 2026 elevated physics-based virtual screening (Sandbox AQ with NVIDIA BioNeMo) over language models, AlphaFold architect John Jumper left DeepMind for Anthropic, and Eli Lilly dominated the deal tape while pure-play techbio names stayed quiet.
- [Lilly Retatrutide Hits 28 Percent Weight Loss and Tirzepatide Passes Keytruda as Top Drug - The Obesity-Drug Pipeline - Week of June 22, 2026](https://www.matterfact.com/newsletter/2026-06-22-glp1-retatrutide-lilly-dethrones-keytruda.md) — 2026-06-22: GLP-1 and obesity-drug newsletter for the week of June 22, 2026. ADA 2026 broke decisively Lilly's way: retatrutide's TRIUMPH-1 posted near-surgical weight loss, the tirzepatide franchise displaced Keytruda as the world's top-selling drug, and contaminated placebo arms quietly became a regulatory problem for everyone chasing the leader.
- [Eli Lilly Gives Hospitals Five Days to Share Claims Data or Lose 340B Discounts as IRA News Goes Quiet - Drug Pricing & IRA Round 2 - Week of June 15–22, 2026](https://www.matterfact.com/newsletter/2026-06-22-drug-pricing-ira-340b-ultimatum.md) — 2026-06-22: For the week of June 22, 2026: Eli Lilly's five-business-day 340B ultimatum letters and AbbVie's bid to rewrite the 340B patient definition dominated the tape, while the core IRA Round 2 negotiation calendar went quiet.
- [uniQure Wins an FDA Path to File Its Huntington's Gene Therapy in Q3 2026 - The Neuro & Alzheimer's Pipeline - Week of June 21, 2026](https://www.matterfact.com/newsletter/2026-06-21-neuro-uniqure-huntingtons-fda-path.md) — 2026-06-21: Neuro and Alzheimer's pipeline newsletter for the week of June 21, 2026. uniQure won a clear FDA path to a Q3 2026 Huntington's gene-therapy filing after a leadership change at the agency, while the anti-amyloid story stayed quiet on the tape and the blood-diagnostic funnel kept widening.
- [Bioprocessing Operators Signal a Capability Shift While No Coverage Stocks Are Named - Life-Science Tools Recovery - Week of June 21, 2026](https://www.matterfact.com/newsletter/2026-06-21-life-science-tools-operators-finally-talk.md) — 2026-06-21: Life-science tools newsletter for the week of June 21, 2026. Two supply-side operators (MilliporeSigma and Cytiva) put the bioprocessing 'capacity to capability' pivot and durable AAV manufacturing demand on the record, even as no coverage-universe pure-play got named on a single podcast.
- [FDA Clears uniQure to File Its Huntington's Gene Therapy Without a Sham-Surgery Control - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of June 21, 2026](https://www.matterfact.com/newsletter/2026-06-21-biotech-pipeline-huntingtons-fda-path-back.md) — 2026-06-21: Gene, cell, neuro and tools newsletter for the week of June 21, 2026. The FDA cleared uniQure to file its Huntington's gene therapy without the sham-surgery control the prior regime demanded, while in-vivo gene/cell therapy became the field's center of gravity and delivery, not the editor, emerged as the real bottleneck.
- [UBS Calls Biotech Back as Record M&A and Patent Cliffs Drive a Recovery - Pharma / Biotech / Life Sciences Podcast Recap - Week of June 21, 2026](https://www.matterfact.com/newsletter/2026-06-21-biotech-is-back-ma-engine.md) — 2026-06-21: Pharma, biotech and life-sciences podcast recap for the week of June 14–21, 2026. UBS's Michael Yee declared 'biotech is back' on the back of a record M&A wave driven by the biggest patent cliffs the industry has ever faced, while ADA and ASCO supplied a flood of GLP-1 and oncology readouts.
- [UNH Framed as a DOJ Risk and CVS Restores Zepbound Coverage in a Quiet Week - Managed Care Under Pressure - Week of June 13-20, 2026](https://www.matterfact.com/newsletter/2026-06-20-managed-care-under-pressure-quiet-investor-tape.md) — 2026-06-20: Managed-care podcast briefing for the week of June 13-20, 2026. The dedicated investor signal went quiet after last week's rich run, leaving two real handles: Telltales reframing UNH as a DOJ binary at ~14x trailing FCF, and CVS Caremark reversing its Zepbound exclusion under ERISA pressure, with Medicaid/ACA cost-shift read-throughs for CNC, MOH and ELV.
- [Drug Pricing Fight Shifts to 340B as Lilly and AbbVie Pressure Hospitals - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 13–20, 2026](https://www.matterfact.com/newsletter/2026-06-20-340b-battle-ira-footnote.md) — 2026-06-20: Healthcare policy newsletter for the week of June 20, 2026 (coverage window June 13–20). The hand-to-hand drug-pricing fight has moved from IRA timelines to 340B, where Lilly is sending hospitals five-day ultimatums and AbbVie is in federal court to narrow the patient definition, while managed care gets squeezed by Medicaid churn and a UnitedHealth billing probe.
- [Biotech M&A Surges as GSK Buys Nuvalent for $10.6B and Lilly Sets a Deal Record - The Biotech Patent Cliff & M&A - Week of June 19, 2026](https://www.matterfact.com/newsletter/2026-06-19-m-a-supercycle-cliffs-look-like-hills.md) — 2026-06-19: Biotech M&A and patent-cliff newsletter for the week of June 19, 2026. The inaugural Issue 001: GSK's $10.6B Nuvalent deal and Lilly's 10-deal pace confirm the supercycle in the print, while a CEO confessional on CVR structure and a patent expert's cliff-is-a-myth thesis reframe the urgency premium.
- [UnitedHealth Looks Cheap but Faces a DOJ Probe as Obesity Drugs Pull Capital to Large-Cap Pharma - The Healthcare Pulse - Week of June 19, 2026](https://www.matterfact.com/newsletter/2026-06-19-healthcare-pulse.md) — 2026-06-19: Weekly healthcare podcast intelligence brief for the week of June 12–19, 2026. Policy hardened around permanent Medicare price negotiation and MFN, UnitedHealth split the tape as cheapest compounder versus a cash engine under subpoena, and the obesity super-cycle kept bending the sector around Lilly's retatrutide data.
- [ADA 2026 Obesity Drug Data Leads as Medicare Pricing and Patent Cliffs Pressure the Sector - Healthcare Podcast Weekly Digest - Week of June 19, 2026](https://www.matterfact.com/newsletter/2026-06-19-healthcare-podcast-digest.md) — 2026-06-19: Healthcare podcast digest for the week of June 13–19, 2026. ADA 2026 turned the GLP-1/obesity race into the dominant story behind Lilly's retatrutide, while permanent Medicare price negotiation, the MFN court fight, H.R. 1's Medicaid cut, and a patent-cliff-driven M&A boom shaped the rest of the tape.
- [Analysts Argue the Keytruda Patent Cliff Is Overstated as GSK and Lilly Keep Buying - The Biotech Patent Cliff & M&A - Week of June 19, 2026](https://www.matterfact.com/newsletter/2026-06-19-cliff-is-a-hill-pharma-keeps-buying.md) — 2026-06-19: Biotech M&A and patent-cliff newsletter for the week of June 19, 2026. A public-interest IP lawyer argues the Keytruda cliff is really a slope while GSK, Lilly and the operators who just sold MetSera and Avidity confirm the supercycle is still printing.
- [GSK Buys Nuvalent for 10.6 Billion Dollars as Pharma Dealmaking Accelerates - The Biotech Patent Cliff & M&A - Week of June 19, 2026](https://www.matterfact.com/newsletter/2026-06-19-biotech-patent-cliff-ma-supercycle.md) — 2026-06-19: Biotech M&A newsletter for the week of June 19, 2026. The patent-cliff supercycle moved from forecast to print with GSK's $10.6B Nuvalent grab and Lilly's record deal pace, while a patent expert argued the cliffs are slower and lumpier than the urgency premiums imply.
- [Cocoa Costs Ease but Chocolate Shelf Prices Stay High as Mondelez Explains the Lag - Food: Brands, Private Label & Grocery - Week of June 18, 2026](https://www.matterfact.com/newsletter/2026-06-18-cocoa-normalized-chocolate-prices.md) — 2026-06-18: For the week of June 18, 2026: Mondelez's CEO says cocoa has normalized while chocolate shelf prices haven't budged, a cocoa bear puts numbers on West Africa's structural decline, and retail media pivots from reach to provable incremental ROAS as the consumer splits K-shaped in volume.
- [Insilico, Latent Labs and Takeda Report AI Design Gains as the Synthesizability Gap Pushes Back - AI Drug Discovery Weekly - Week of June 18, 2026](https://www.matterfact.com/newsletter/2026-06-18-ai-drug-discovery-productivity-synthesizability.md) — 2026-06-18: AI drug discovery newsletter for the week of June 11–18, 2026. Insilico, Latent Labs, and Takeda put hard productivity numbers behind their AI-design claims, while a dedicated episode on the synthesizability gap supplies the counterweight.
- [Eli Lilly Pays About 3 Billion Dollars for an In-Vivo CAR-T Developer as In-Vivo Cell Therapy Gains Validation - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of June 14, 2026](https://www.matterfact.com/newsletter/2026-06-14-in-vivo-lilly-car-t.md) — 2026-06-14: Gene, cell, neuro and tools newsletter for the week of June 14, 2026. In-vivo cell therapy got a price tag as Eli Lilly paid ~$3B upfront for an in-vivo CAR-T developer, 4DMT aimed a one-shot retinal gene therapy at the ~$20B anti-VEGF market, and RNA-editing operators leaned into reversibility.
- [CMS Finalizes a 2.5 Percent 2027 Medicare Advantage Rate and Defers the V28 Risk Model Reset - Managed Care Under Pressure - Week of June 6–13, 2026](https://www.matterfact.com/newsletter/2026-06-13-managed-care-ma-2027-rate-clears.md) — 2026-06-13: Managed-care podcast briefing for the week of June 6–13, 2026. CMS finalized a roughly +2.5% 2027 Medicare Advantage rate and shelved the V28 risk-model change to 2028, while enacted federal PBM reform and Medicaid SDP caps deepened the multi-year overhang for UNH, CVS, ELV, CNC and MOH.
- [2027 Medicare Advantage Rate Beats Fears While IRA and MFN Pressure Drug Pricing - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 13, 2026](https://www.matterfact.com/newsletter/2026-06-13-healthcare-policy-ma-break-pricing-squeeze.md) — 2026-06-13: Healthcare-policy podcast briefing for the week of June 13, 2026. The 2027 Medicare Advantage rate landed better than the January scare, but the IRA pill penalty, Most Favored Nation pricing and a coordinated hospital reimbursement reset tightened the squeeze across UNH, LLY, ELV and the hospital names.
- [GSK Buys Nuvalent for 10.6 Billion as Lilly Stocks Up on Early-Stage Drugs - The Biotech Patent Cliff & M&A - Week of June 12, 2026](https://www.matterfact.com/newsletter/2026-06-12-biotech-patent-cliff-lilly-buys-future.md) — 2026-06-12: Biotech M&A and patent-cliff newsletter for the week of June 12, 2026. The deal dam broke with GSK's $10.6B Nuvalent buyout and four more bolt-ons, splitting the cohort into Lilly buying 2032 science from strength while Merck, Pfizer, BMY and J&J still buy late-stage to plug LOE holes.
- [Billion-Dollar Biopharma Deals Tripled as a New Bill Targets US-China Pharma Pacts - The Biotech Patent Cliff & M&A - Week of June 12, 2026](https://www.matterfact.com/newsletter/2026-06-12-biopharma-deals-tripled-washington.md) — 2026-06-12: Biotech M&A and patent-cliff newsletter for the week of June 12, 2026. RBC's bankers quantified the supercycle with billion-dollar life-sciences deals tripling year over year, a new bipartisan bill put US-China pharma deals under Treasury review and named Pfizer and Bristol-Myers, and Merck restated its post-Keytruda diversification plan.
- [An Open Source Protein Model Designs Lab Validated Antibodies - AI Drug Discovery Weekly - Week of June 11, 2026](https://www.matterfact.com/newsletter/2026-06-11-ai-drug-discovery-open-source-protein-models.md) — 2026-06-11: AI drug discovery newsletter for the week of June 11, 2026. The platform debate moved on real insider tape: a CZ Biohub protein language model designed cryo-EM-validated nanomolar antibodies, NVIDIA called simulation assay-grade and named Schrodinger, and the first AI-formulated oral drug entered Phase 1.
- [Beam Says FDA Will Allow a Biomarker Endpoint to Speed Approval of In-Vivo Gene Editing - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of June 7, 2026](https://www.matterfact.com/newsletter/2026-06-07-biomarker-fast-lane-in-vivo-editing.md) — 2026-06-07: Biotech pipeline newsletter for the week of June 7, 2026, covering gene/cell editing, neuro and tools. Beam's chief scientist argues in-vivo base editing now has a biomarker-endpoint shortcut to accelerated approval, while a frontline neurology pharmacist gives an unvarnished read on how the anti-amyloid launches are actually landing in clinic.
- [New CMS Rule Caps Medicaid Payments and PBM Reform Becomes Law - Managed Care Under Pressure - Week of May 30 – June 6, 2026](https://www.matterfact.com/newsletter/2026-06-06-managed-care-under-pressure.md) — 2026-06-06: Managed care newsletter for the week of May 30 to June 6, 2026. A new CMS rule caps Medicaid state-directed and supplemental payments at 100% to 110% of Medicare by 2029, and PBM reform crossed from theme into signed legislation, while operator guidance stayed off tape.
- [IRA Pill Penalty Pushes Pharma Toward Biologics While Medicaid Funding Cuts Loom in 2027 - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of June 6, 2026](https://www.matterfact.com/newsletter/2026-06-06-healthcare-policy-pill-penalty-medicaid.md) — 2026-06-06: Healthcare policy newsletter for the week of June 6, 2026. The IRA pill penalty is already bending pharma capital toward biologics and rare-disease franchises, Medicaid's real cliff is back-loaded to 2027 as provider bankruptcies climb, and most-favored-nation pricing remains vibes rather than legislation.
- [Pfizer's $10.5B Innovent Oncology Deal Headlines a Pharma Dealmaking Sprint With Lilly and ASCO Wins - The Biotech Patent Cliff & M&A - Week ending Friday, June 5, 2026](https://www.matterfact.com/newsletter/2026-06-05-biotech-pfizer-innovent.md) — 2026-06-05: Pharma and biotech newsletter for the week ending Friday, June 5, 2026. Pfizer's up-to-$10.5B Innovent oncology collaboration headlines a dealmaking sprint, Lilly fires off four licensing deals in five days, and ASCO derisks the SMID takeout targets while Eli Lilly's CEO frames GLP-1 dominance on The Prof G Pod.
- [Isomorphic Labs Raises $2.1B at a $10B Valuation With 173 AI Drug Programs in Trials and None Approved - AI Drug Discovery - Week of May 28 – Jun 4, 2026](https://www.matterfact.com/newsletter/2026-06-04-ai-drug-discovery.md) — 2026-06-04: AI drug discovery newsletter for the week of May 28 to June 4, 2026. Isomorphic Labs' $2.1B raise at a reported ~$10B valuation crystallized the bull/bear fault line, with 173 AI-originated programs in the clinic and none yet approved, while Eli Lilly's CAIO laid out a de-risking-not-speed thesis and Recursion and Schrödinger rallied without a word of podcast coverage.
- [FDA Commissioner Makary Resigns and ASCO Fuels a Roughly 75 Billion Dollar Pharma Deal Wave - The Biotech Patent Cliff & M&A - Week of June 1, 2026](https://www.matterfact.com/newsletter/2026-06-01-pharma-ma-makary-asco.md) — 2026-06-01: Pharma and biotech newsletter for the week of May 28 to June 1, 2026. FDA Commissioner Marty Makary resigns and biotech loses its predictability anchor, while ASCO 2026 puts oncology back center stage and operators name the Inflation Reduction Act as the forcing function behind a roughly $75B pharma M&A wave.
- [Half of IRA Round 1 Drugmakers Already Cut List Price and AbbVie Drops Imbruvica to the Negotiated Rate - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of May 25 – June 1, 2026](https://www.matterfact.com/newsletter/2026-06-01-drug-pricing-ira-round2.md) — 2026-06-01: Drug pricing and IRA newsletter for the week of May 25 to June 1, 2026. Five of the ten Round 1 manufacturers have already cut list price, with AbbVie's Imbruvica taken all the way down to MFP, the first concrete sign the IRA bleeds into commercial gross-to-net.
- [Novo Nordisk Cuts Wegovy Prices and Battles Eli Lilly for the Obesity Drug Lead - Pharma / Biotech Podcast Recap - Week of May 24–31, 2026](https://www.matterfact.com/newsletter/2026-05-31-pharma-biotech-podcast-recap.md) — 2026-05-31: Pharma, biotech, and life-sciences podcast recap for May 24–31, 2026. A thin, GLP-1-dominated week pits Novo Nordisk's Wegovy pill launch and aggressive list-price cuts against Eli Lilly's pipeline lead and an $18.6B diversification push.
- [Biogen's Tau Drug Misses Its Main Goal but Shows an Alzheimer's Subgroup Signal - The Neuro & Alzheimer's Pipeline - Week of May 24–31, 2026](https://www.matterfact.com/newsletter/2026-05-31-neuro-alzheimers-pipeline-biogen.md) — 2026-05-31: Neuro and Alzheimer's pipeline newsletter for May 24–31, 2026. Biogen's anti-tau Derenersen misses its Phase II primary but flags an AD subgroup signal, while the blood-biomarker complex keeps racing ahead and big-company launch commentary stays conspicuously quiet.
- [Lilly's Retatrutide Shows 28% Weight Loss and Novo Cuts Wegovy List Price by Half - The GLP-1 Complex - Week of May 25–28, 2026](https://www.matterfact.com/newsletter/2026-05-31-glp1-complex-retatrutide.md) — 2026-05-31: GLP-1 complex newsletter for the week of May 25–28, 2026. Lilly's retatrutide top-line pulls bariatric surgery into a price fight while Novo's CEO concedes the branded list-price ceiling ahead of ADA.
- [Big Pharma Licenses More Drugs From China and Bypasses US Biotech Startups - Biotech Pipeline: Gene/Cell, Neuro & Tools - Week of May 25–31, 2026](https://www.matterfact.com/newsletter/2026-05-31-biotech-pipeline-china.md) — 2026-05-31: Biotech podcast newsletter for May 25–31, 2026. The headline gene/cell, anti-amyloid, and tools tapes were quiet, while the dominant argument was structural: big pharma is licensing its next decade of assets straight out of China, with the Wuxi Biologics / Viridian deal as the real-time tell.
- [AbbVie Cuts Imbruvica List Price to the Medicare Negotiated Rate as IRA Effects Spread - Drug Pricing & IRA Round 2 - Week of May 24–30, 2026](https://www.matterfact.com/newsletter/2026-05-30-drug-pricing-ira.md) — 2026-05-30: AbbVie reset Imbruvica's commercial WAC to MFP and it's already cascading to PBM reimbursement, Richard Pops put a number on the small-molecule pill penalty, and CMS's 2028 pool adds Part B drugs for the first time.
- [Lilly Spends 18 Billion on Early-Stage Deals as the Patent Cliff Drives Pharma M&A - Biotech Patent Cliff & M&A - Week of May 30, 2026](https://www.matterfact.com/newsletter/2026-05-30-biotech-patent-cliff.md) — 2026-05-30: Lilly deployed ~$18.6B in early-stage M&A in 30 days, Merck's pre-ASCO Keytruda combo cut PFS/death risk 65%, and the XBI/IBB divergence is signaling a buy-side bet on takeout premiums.
- [Private AI Biotech Soley Sets Fast Cycle-Time Benchmark While Recursion and Schrodinger Stay Quiet - AI Drug Discovery - Week of May 23–30, 2026](https://www.matterfact.com/newsletter/2026-05-30-ai-drug-discovery.md) — 2026-05-30: A private CEO set the platform bar at 8 to 10 month med-chem cycles, RXRX and SDGR went quiet, and Lilly went on a $3.83B vaccine M&A spree.
- [Eli Lilly Retatrutide Data, Novo Nordisk Comeback Pitch, and Tennessee PBM Crackdown - The Healthcare Pulse - Week of May 29, 2026](https://www.matterfact.com/newsletter/2026-05-29-healthcare-pulse.md) — 2026-05-29: Weekly healthcare podcast intelligence brief for May 22–29, 2026. The GLP-1 story dominated: Eli Lilly's Triumph-1 retatrutide readout, Novo Nordisk CEO Mike Doustdar's comeback pitch, and Tennessee's Fair Rx Act as a structural shot at the PBMs.
- [Eli Lilly Retatrutide Trial Posts Record Weight Loss as ASCO 2026 Cancer Readouts Loom - Healthcare Podcast Weekly Digest - Week of May 23–29, 2026](https://www.matterfact.com/newsletter/2026-05-29-healthcare-podcast-digest.md) — 2026-05-29: Healthcare podcast digest for May 23–29, 2026. Eli Lilly's retatrutide blowout and a triple vaccine roll-up, the ASCO 2026 plenary setup (Revolution Medicines pan-RAS and Summit/Akeso ivonescimab), UnitedHealth's Medicare Advantage rerate, and FDA leadership upheaval.
- [Pfizer CEO Bourla Argues the COVID Revenue Cliff Is Behind Them and the Turnaround Is Working - Pfizer (PFE) Podcast Intelligence Newsletter - Week of May 20–24, 2026](https://www.matterfact.com/newsletter/2026-05-24-pfe-bourla-pushes-turnaround-narrative.md) — 2026-05-24: Pfizer investor newsletter for May 20–24, 2026. CEO Albert Bourla works the podcast circuit as PFE listeners weigh pipeline progress against the looming patent cliff.
- [Lilly's Retatrutide Readout Drives the Obesity Drug Debate as Investors Rotate Into Legacy Pharma - The Healthcare Pulse - Weekly Podcast Intelligence Brief, May 15–22, 2026](https://www.matterfact.com/newsletter/2026-05-22-healthcare-pulse.md) — 2026-05-22: Healthcare investor newsletter for May 15–22, 2026. Eli Lilly's Phase 3 retatrutide readout anchors the GLP-1 debate while the tape rotates into legacy pharma, and a policy stack from SCOTUS to TrumpRx resets the structural backdrop.
- [Lilly's TRIUMPH-1 Retatrutide Results Set the Tone Heading Into the ASCO Cancer Conference - Healthcare Podcast Weekly Digest - Week of May 18 – May 22, 2026](https://www.matterfact.com/newsletter/2026-05-22-healthcare-podcast-digest.md) — 2026-05-22: Healthcare podcast digest for May 18–22, 2026. Eli Lilly's TRIUMPH-1 retatrutide readout, Pfizer CEO Bourla's China and monthly GLP-1 thesis, and an FDA leadership reset heading into ASCO 2026.
- [Lilly Widens Its Obesity Drug Lead Over Novo as the FDA Commissioner Resigns - The Healthcare Pulse: Weekly Podcast Intelligence Brief - Week of May 8 – May 15, 2026](https://www.matterfact.com/newsletter/2026-05-15-healthcare-pulse.md) — 2026-05-15: Healthcare investor newsletter for May 8 – May 15, 2026. The FDA leadership vacuum after Marty Makary's exit, the Lilly vs. Novo GLP-1 showdown at the European Congress on Obesity, and the Medicare Advantage era of austerity, synthesized across seven podcasts and ticker-level news.
- [FDA Commissioner Makary Resigns and Eli Lilly Q1 Results Drive a Biotech Rotation - Healthcare Podcast Weekly Digest - Week of May 8 – May 15, 2026](https://www.matterfact.com/newsletter/2026-05-15-healthcare-podcast-digest.md) — 2026-05-15: Healthcare podcast synthesis for May 8–15, 2026. FDA Commissioner Makary resigns, Eli Lilly's blowout Q1 lifts the GLP-1 bull case, and the biotech rotation toward developmental-stage names accelerates.
- [Pfizer Q1 Beat and Vyndamax Patent Extension Support the 2029 Revenue Recovery Case - Pfizer (PFE) Investor Newsletter - Week of May 6–10, 2026](https://www.matterfact.com/newsletter/2026-05-10-pfizer-vyndamax-2029-turnaround.md) — 2026-05-10: Pfizer investor newsletter for May 6–10, 2026. Podcasts test how Vyndamax (tafamidis) supports the PFE bull case for a 2029 revenue recovery beyond the patent cliff.
- [Novo Oral Wegovy Outsells Eli Lilly Pill as Drug Pricing Reset Accelerates - The Healthcare Pulse: Weekly Podcast Intelligence Brief - Week of May 1 – May 8, 2026](https://www.matterfact.com/newsletter/2026-05-08-healthcare-pulse.md) — 2026-05-08: Weekly healthcare-investor podcast intelligence brief for May 1 – May 8, 2026. The oral GLP-1 narrative flips toward Novo's oral Wegovy, the global pricing reset accelerates, and FDA leadership instability becomes a recurring investor debate.
- [FDA Moves Against Compounded GLP-1s as Eli Lilly's Strong Q1 Lifts Healthcare Stocks - Healthcare Podcast Weekly Digest - May 2 – 8, 2026](https://www.matterfact.com/newsletter/2026-05-08-healthcare-podcast-digest.md) — 2026-05-08: Healthcare podcast and news synthesis for May 2–8, 2026. Eli Lilly's blowout Q1 and Foundayo launch, an FDA move against compounded GLP-1s, UnitedHealth's underwriting-cycle inflection, and the AI inflationary-vs-deflationary debate.
- [Eli Lilly Q1 Earnings and Acquisitions Reshape the Obesity Drug Race - The Healthcare Pulse - Week of April 24 – May 1, 2026](https://www.matterfact.com/newsletter/2026-05-01-healthcare-pulse.md) — 2026-05-01: Healthcare podcast intelligence brief for April 24 – May 1, 2026. Eli Lilly's Q1 blowout and M&A spree reframe the obesity narrative while sector-wide dealmaking, an FDA AI-trial pilot, and an Amgen Tavneos regulatory cloud dominate the tape.
- [Eli Lilly Posts a Strong Q1 and the FDA Restricts GLP-1 Compounding - Healthcare Podcast Weekly Digest - Week of April 27 – May 1, 2026](https://www.matterfact.com/newsletter/2026-05-01-healthcare-podcast-digest.md) — 2026-05-01: Healthcare sector podcast and news synthesis for April 27 – May 1, 2026. Eli Lilly's blowout Q1 and the Foundayo oral GLP-1 launch, UnitedHealth's turnaround quarter, the FDA's 503B compounding crackdown, and a biopharma M&A market running its hottest in years.
- [Pfizer CFO Lays Out a 2029 Growth Reset and Defends the Long Term Thesis - Pfizer (PFE) Podcast Newsletter - Week of April 21-26, 2026](https://www.matterfact.com/newsletter/2026-04-26-pfizer-2029-growth-reset.md) — 2026-04-26: Pfizer investor newsletter for Apr 20–26, 2026. CFO Dave Denton lays out a candid 2029 reset, defending the long-thesis even as near-term challenges divide PFE holders.
- [UnitedHealth Beat and a Biotech Rally Meet a Lilly Bull Bear Fight and a Merck Trial Miss - The Healthcare Pulse: Weekly Podcast Intelligence Brief - Week of April 17 – April 24, 2026](https://www.matterfact.com/newsletter/2026-04-24-healthcare-pulse.md) — 2026-04-24: Podcast-sourced healthcare brief for April 17–24, 2026. UnitedHealth's Q1 beat and a ripping biotech tape meet a widening payer/provider split, an acrimonious bull/bear fight over Eli Lilly, and Merck's LITESPARK-012 pipeline miss.
- [UnitedHealth Q1 Beat and Eli Lilly Oral GLP-1 Launch Reshape the Obesity Drug Race - The Healthcare Investor Brief - Week of April 18–24, 2026](https://www.matterfact.com/newsletter/2026-04-24-healthcare-podcast-digest.md) — 2026-04-24: Healthcare investor newsletter for April 18–24, 2026. UnitedHealth's blowout Q1 turnaround squares off against valuation skeptics, while Eli Lilly's oral GLP-1 launch, the Kelonia CAR-T deal, and an Amazon/Hims pharmacy reconfiguration redraw the obesity battle map.
- [Lilly Launches Foundayo and Opens the Oral GLP-1 Race Amid an M&A Surge and a Favorable Medicare Advantage Rate - The Healthcare Pulse: Weekly Podcast Intelligence Brief - Week of April 10–17, 2026](https://www.matterfact.com/newsletter/2026-04-17-healthcare-pulse.md) — 2026-04-17: Podcast-sourced healthcare brief for April 10–17, 2026. The GLP-1 oral wars go live with Lilly's Foundayo launch, while M&A, the biotech rally, and a favorable Medicare Advantage rate reshape the sector.
- [Eli Lilly's Foundayo Launch and Strong Heart Data Drive a Managed Care Rally on the New Medicare Advantage Rate - Healthcare Podcast Weekly Digest - Week of April 10–17, 2026](https://www.matterfact.com/newsletter/2026-04-17-healthcare-podcast-digest.md) — 2026-04-17: Healthcare podcast and news synthesis for April 10–17, 2026. Eli Lilly's Foundayo launch and ACHIEVE-4 data, a managed care rally on the finalized CMS Medicare Advantage rate, and a record-pace M&A environment frame the sector.
- [Oral GLP-1 Drugs Launch From Novo and Lilly as a Higher Medicare Advantage Rate Lifts Managed Care - Healthcare Podcast Weekly Digest - Week of April 7–13, 2026](https://www.matterfact.com/newsletter/2026-04-15-healthcare-podcast-digest.md) — 2026-04-15: A podcast-sourced healthcare digest for the week of April 7–13, 2026. Oral GLP-1 launches, a generous CMS rate hike for managed care, and a record M&A pace dominate the tape as biotech outperforms.
- [Pfizer Still Faces 100 Percent Drug Tariffs Despite Its White House Exemption Deal - Pfizer and Pharma Sector Newsletter - Week of April 12, 2026](https://www.matterfact.com/newsletter/2026-04-12-pfizer-tariff-exemption-uncertainty.md) — 2026-04-12: Pfizer investor newsletter for Apr 6–12, 2026. Tariff exemption uncertainty grips big pharma as podcasts gauge what an unfavorable ruling means for PFE.
- [Pfizer Expands AI Use in Oncology Research Amid Policy Tailwinds - Pfizer ($PFE) Weekly Intelligence Brief - Week of April 05, 2026](https://www.matterfact.com/newsletter/2026-04-05-pfizer-ai-and-policy-tailwinds.md) — 2026-04-05: Pfizer investor newsletter for Mar 30–Apr 5, 2026. Thin podcast coverage spotlights AI-driven oncology, AMR engagement, and policy tailwinds at PFE.
- [Pfizer Screens as a Defensive Dividend Hold With a 6.4 Percent Yield and Limited Growth - Pfizer Inc. ($PFE) Investor Newsletter - Week of March 29, 2026](https://www.matterfact.com/newsletter/2026-03-29-pfizer-defensive-hold-dividend-strength-limited-upside.md) — 2026-03-29: Pfizer investor newsletter for Mar 23–29, 2026. PFE screens as a defensive dividend play with improving non-COVID momentum but capped upside, per podcast coverage.

---

Related: [all newsletters](https://www.matterfact.com/newsletter.md) · [full corpus](https://www.matterfact.com/llms-full.txt)